Advertisement
Document › Details
Oxford Nanopore Technologies Ltd.. (10/18/17). "Press Release: WuXi NextCODE Integrates Oxford Nanopore into the Global Platform for Genomic Data". Shanghai, Cambridge, MA & Reykjavik.
Region | Shanghai | |
Country | China | |
Organisation | Oxford Nanopore Technologies Ltd. | |
Today | Oxford Nanopore Technologies plc (LSE: ONT) | |
Group | Oxford Nanopore (Group) | |
Organisation 2 | WuXi NextCode | |
Product | nanopore DNA sequencer | |
Product 2 | DNA sequencing service | |
Person | Smarason, Hannes (WuXi PharmaTech 201709 CEO of WuXi NextCode) | |
Person 2 | Sanghera, Gurdial (Gordon) (Oxford Nanopore 201907 CEO before Oxford NanoLabs 200506 CEO) | |
• Long-read, real-time DNA and RNA sequencing now available to researchers and clinical scientists through China’s preeminent and most comprehensive CLIA/CAP laboratory
• WuXi NextCODE partners can now combine nanopore sequencing and the world’s leading informatics to solve genomics challenges with the potential to improve health
WuXi NextCODE, the contract genomics organization providing the global standard platform for genomic data, today announced the first open-access installation of Oxford Nanopore instruments in a CAP/CLIA lab in China – at WuXi NextCODE’s sequencing laboratory in Shanghai.
“We are honored to introduce Oxford Nanopore’s pathbreaking capabilities to the breadth of the scientific and medical community in China,” said Hannes Smarason, CEO of WuXi NextCODE. “Pioneering access to world-leading leading technology is at the heart of our mission and tradition, so this important new source of sequence data has an important place in our global platform and Shanghai lab. Coupled with our informatics it promises to open new and powerful applications from discovery to rapid, direct-read diagnostics. We and Oxford Nanopore invite researchers across China to use it, challenge it, and extend its applications to improve health and medicine here and around the world.”
“We are delighted that WuXi NextCODE will be offering nanopore sequencing to its clientele across China and the world through its Shanghai laboratory,” said Gordon Sanghera, CEO of Oxford Nanopore. “China’s world-class scientists can use nanopore technology whether they are researching DNA or RNA, human, plant, bacteria or microbiomes, all of which benefit from ultra-long reads and direct real-time sequencing, and also access WuXi NextCODE’s renowned informatics. We look forward to contributing to great science in China.”
Nanopore sequencing works by passing a strand of DNA through a nano-scale hole (“nanopore”) while passing an ionic current through that hole. The sequence of DNA or RNA is determined by measuring variations in the current as strands pass through the nanopore. Unlike other sequencing techniques, it does not require cutting genomes into millions of fragments only hundreds of bases long and preparing them with primers and reagents. As a result, even single handheld instruments can quickly and economically produce reads that are hundreds of thousands of bases long, and users around the world are now attempting to achieve the first one million-base read. The same instruments can also be used to sequence RNA directly or sequence cDNA, producing full length transcripts.
About WuXi NextCODE
WuXi NextCODE is a fully integrated contract genomics organization building the global standard platform for genomic data. With offices in Shanghai; Kendall Square in Cambridge, Massachusetts; and Reykjavik, Iceland, we serve the leading population genomics, precision medicine, diagnostics and wellness initiatives and enterprises using the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China. WuXi NextCODE is a WuXi Group company. Visit us on the web at www.wuxinextcode.com.
Record changed: 2023-06-05 |
Advertisement
More documents for Oxford Nanopore (Group)
- [1] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
- [2] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
- [3] Oxford Nanopore Technologies plc. (10/4/21). "Press Release: Exercise of Over-allotment Option [Not for US, CA, JP, AU, et al.]"....
- [4] Oxford Nanopore Technologies plc. (9/30/21). "Press Release: Pricing Statement [Not for US, CA, JP, AU, et al.]"....
- [5] Oxford Nanopore Technologies Ltd.. (9/16/21). "Press Release: Confirmation of Intention to Float [Not for US, CA, JP, AU, et al.]"....
- [6] Oxford Nanopore Technologies Ltd.. (9/9/21). "Press Release: Announcement of Intention to Publish a Registration Document and Expected Intention to Float on the London Stock Exchange [Not for US, CA, JP, AU, et al.]"....
- [7] Nvidia Corporation. (7/6/21). "Press Release: Nvidia Launches UK’s Most Powerful Supercomputer, for Research in AI and Healthcare"....
- [8] IP Group plc. (5/4/21). "Press Release: Portfolio Company Oxford Nanopore Technologies Raises £195m in New Investment"....
- [9] Oxford Nanopore Technologies Ltd.. (7/8/19). "Press Release: Scale-up – Oxford Nanopore’s New High-tech Factory Comes Online". Oxford....
- [10] Amgen Inc.. (10/18/18). "Press Release: Amgen Invests £50 Million ($66 Million) in Oxford Nanopore Technologies". Thousand Oaks, CA & Oxford....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top